PMID- 30473540
OWN - NLM
STAT- MEDLINE
DCOM- 20190722
LR  - 20200225
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 38
IP  - 6
DP  - 2018 Dec 21
TI  - Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with 
      non-alcoholic fatty liver disease.
LID - BSR20181304 [pii]
LID - 10.1042/BSR20181304 [doi]
AB  - Type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver 
      disease (NAFLD) is difficult to treat. The present study explored the efficacy of 
      (liraglutide) Lira in treating T2DM complicated with NAFLD. A total of 127 
      patients suffering from T2DM complicated with NAFLD were enrolled in the present 
      study, and randomly assigned to a Lira group (liraglutide injection: 0.6-1.2 
      mg/day, 12 weeks, n=52) or a Metformin (Met) group (oral metformin: 1000-1500 
      mg/day, 12 weeks, n=75). During the treatment phase, the values for fasting 
      plasma glucose (FPG), 2 h plasma glucose (2hPG), glycated hemoglobin (HbA1c), 
      aspartate aminotransferase (AST)/alanine aminotransferase (ALT), and adiponectin 
      (APN) decreased in both the Lira and Met groups, and the levels of Delta2hPG, 
      DeltaAST/ALT, and DeltaAPN in the Lira group were significantly lower than those in the 
      Met group. The values for total cholesterol (TC), triglycerides (TG), low-and 
      high-density lipoproteins (LDL and HDL), ALT, AST, weight, body mass index (BMI), 
      waist to hip ratio (WHR), and C-reactive protein were markedly increased in both 
      groups, and levels of DeltaAST, DeltaALT, Deltaweight, DeltaBMI, DeltaWHR, and DeltaCRP (C-reactive 
      protein) in the Lira group were significantly higher than those in the Met group. 
      An analysis of treatment efficacy showed that liraglutide was better than 
      metformin in its ability to significantly decrease the ALT levels in patients 
      with combined T2DM and NAFLD. Furthermore, liraglutide was more effective than 
      metformin at ameliorating the severity of T2DM complicated with NAFLD, and 
      produced its effects by alleviating liver inflammation and improving liver 
      function.
CI  - (c) 2018 The Author(s).
FAU - Tian, Feng
AU  - Tian F
AD  - Department of Endocrinology and Metabolism, Shenzhen Guangming New District 
      People's Hospital, Shenzhen 518000, China.
FAU - Zheng, Zhigang
AU  - Zheng Z
AD  - Department of Internal Medicine, Shenzhen Yantian District People's Hospital, 
      Shenzhen 518000, China.
FAU - Zhang, Damin
AU  - Zhang D
AD  - Department of Internal Medicine, Shenzhen Yantian District People's Hospital, 
      Shenzhen 518000, China.
FAU - He, Si
AU  - He S
AD  - Department of Internal Medicine, Shenzhen Yantian District People's Hospital, 
      Shenzhen 518000, China.
FAU - Shen, Jie
AU  - Shen J
AUID- ORCID: 0000-0002-7906-9187
AD  - Department of Endocrinology and Metabolism, The Third Affiliated Hospital of 
      Southern Medical University, Guangzhou 510500, China sarahtina6@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20181221
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (ADIPOQ protein, human)
RN  - 0 (Adiponectin)
RN  - 0 (Blood Glucose)
RN  - 0 (Triglycerides)
RN  - 839I73S42A (Liraglutide)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
SB  - IM
MH  - Adiponectin/blood
MH  - Alanine Transaminase/blood
MH  - Aspartate Aminotransferases/blood
MH  - Blood Glucose
MH  - Body Mass Index
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Liraglutide/*administration & dosage
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/blood/complications/*drug therapy/pathology
MH  - Triglycerides/blood
MH  - Waist-Hip Ratio
PMC - PMC6435530
OTO - NOTNLM
OT  - Liraglutide
OT  - Metformin
OT  - Non-alcoholic fatty liver disease
OT  - Type 2 diabetes mellitus
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2018/11/27 06:00
MHDA- 2019/07/23 06:00
PMCR- 2018/12/21
CRDT- 2018/11/27 06:00
PHST- 2018/08/01 00:00 [received]
PHST- 2018/11/07 00:00 [revised]
PHST- 2018/11/16 00:00 [accepted]
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2019/07/23 06:00 [medline]
PHST- 2018/11/27 06:00 [entrez]
PHST- 2018/12/21 00:00 [pmc-release]
AID - BSR20181304 [pii]
AID - 10.1042/BSR20181304 [doi]
PST - epublish
SO  - Biosci Rep. 2018 Dec 21;38(6):BSR20181304. doi: 10.1042/BSR20181304. Print 2018 
      Dec 21.